logo-loader
viewAstraZeneca

AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial

The drug failed to prolong the lives of patients with advanced head and neck cancers when it was used alone or in combination with another treatment, in comparison to standard chemo

head x ray
Imfinzi has so far struggled to treat late-stage cancers

One of AstraZeneca PLC’s (LON:AZN) key new drugs Imfinzi has failed in yet another late-stage clinical trial, this time in advanced head and neck cancer.

The drug was tested both on its own and in combination with tremelimumab but neither improved overall survival any more than standard chemotherapy.

“While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer,” said chief medical officer Sean Bohen.

“We look forward to seeing the results of the phase III KESTREL trial of Imfinzi and tremelimumab in patients who have not received prior chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma in the first half of 2019.”

READ: AZN in cancer drug setback

Imfinzi is one of AstraZeneca’s potential star assets and had been expected to generate annual sales of more than US$2.5bn from 2022.

It has previously been approved for use in earlier stage lung cancer the cant be removed without surgery, and AstraZeneca has been carrying out further trials that may support its use in other indications.

But the drug has now failed two late-stage trials in less than a month. On top of today’s disappointed, it also failed to prolong the lives of patients with advanced lung tumours.

Imfinzi’s failure in treating late-stage cancer patients, along with other setbacks, will make it difficult for the FTSE 100 group to hit the US$40bn of sales its chief executive Pascal Soriot had promised to achieve by 2023.

Astra shares were broadly unchanged at 5,950p in early deals on Friday.

Quick facts: AstraZeneca

Price: 7258 GBX

LSE:AZN
Market: LSE
Market Cap: £95.22 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Impax Asset Management reveals key themes investors should...

Impax Asset Management Group PLC (LON:IPX) Head of Client Services and Business Development David Richardson tells Proactive key themes investors should look out for in 2020.  Richardson says he's seeing expansion in developing renewable energy projects in Europe, increased interested in...

21 hours, 52 minutes ago

2 min read